World Health Organization (WHO) and European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an 5 year agreement to develop a strategic roadmap on bone health and ageing
more than 7000 women aged 60 and over from five countries has revealed that broken bones affect almost one in two women in this age group, and that, paradoxically, bone health is neglected during medical check-ups.
Osteoporosis is a condition characterized by weakened and brittle bones, elevating the risk of fractures. Often termed a “silent” disease, it manifests without symptoms until a bone breaks. The root cause is an imbalance between the slower production of new bone tissue and the faster loss of old bone tissue. Treatment objectives for osteoporosis focus on slowing or halting bone loss and preventing fractures.
PREVENTION
PREVENTION
Diet: Ensure a balanced diet rich in protein, calories, calcium, and vitamin D.
Calcium Intake: Consume at least 1000 mg of calcium daily for premenopausal women and men; postmenopausal women should aim for 1200 mg daily.
Vitamin D: Get 800 IU (20 mcg) of vitamin D daily for men over 70 and postmenopausal women.
Alcohol: Limit alcohol intake to reduce fracture risk.
Exercise: Engage in regular physical activity for at least 30 minutes, three times per week.
Smoking: Quit smoking to prevent accelerated bone loss.
Fall Prevention: Take measures to avoid falls, such as removing tripping hazards and ensuring good lighting at home.
TREATMENT
TREATMENT
Medications: Consider medication if at high risk of fracture, as determined by bone density and other risk factors.
Bisphosphonates: Commonly prescribed drugs to slow bone breakdown; examples include alendronate, risedronate, ibandronate, and zoledronic acid.
Selective Estrogen Receptor Modulators (SERMs): Medications like raloxifene and tamoxifen provide estrogen-like effects in the bone, reducing bone loss and fracture risk.
Hormone Therapy: Estrogen therapy may be considered for postmenopausal women for relief of menopausal symptoms and bone loss prevention.
Denosumab: A biologic drug that blocks bone-breakdown cells, given every six months via injection.
Anabolic Agents: Stimulate bone formation and include teriparatide (PTH) or PTH-related protein analogs, as well as romosozumab, which blocks a protein that inhibits new bone formation.